Innopiphany

Missed the live discussion? Watch the recording of our recent webinar on Medicare negotiations for expert insights from former CMS Commissioner Dr. Mark McClellan and Innopiphany Principal Dr. Brad Stolshek: https://lnkd.in/g9KmePaz #IRA #MedicareNegotiations #HealthPolicy #Webinar

Last chance to register for tomorrow's webinar! Sign up here: https://lnkd.in/gZ98SqJS

One week away! Don't miss out on expert insights from former CMS Commissioner Dr. Mark McClellan and Innopiphany Principal Dr. Brad Stolshek on what the first round of IRA Medicare negotiations could mean for next year. Register here: https://lnkd.in/gZ98SqJS Date: Thursday September 12th, 2024 Time: 8 AM PT / 11 AM ET Location: Zoom #IRA #MedicareNegotiations #HealthPolicy #Webinar

In our recent webinar, “From Policy to Practice: How Prescription Drug Affordability Boards May Impact Patients," we heard experts discuss the unintended consequences that could occur due to PDABs. Here are some of the key takeaways! Watch the full recording here: https://lnkd.in/gpU_EvVq #HealthPolicy #PDAB #Webinar #DrugPricing #PatientAccess

Upcoming Free Webinar: "IRA Medicare Negotiations: What the First Round Means for Next Year" Register here: https://lnkd.in/gZ98SqJS   Join the conversation on the recently released Medicare negotiated prices and their implications for next year with former CMS commissioner Mark McClellan and Innopiphany Principal Brad Stolshek. You don't want to miss it! Date: September 12th, 2024 Time: 8 - 9 AM PT / 11 AM - 12 PM ET Location: Zoom   #IRA #Medicare #Webinar #CMS #DrugPricing

Medicare's negotiated prices for Stelara® and Enbrel® were the closest to each drug's statutory discount, while Xarelto®, Jardiance®, and Farxiga® were subject to deeper cuts. We won't know why until next year, when CMS releases its pricing explanation. However, the next round of negotiations will begin before then, leaving manufacturers to fumble in the darkness of a methodological blackbox. Want to learn what can be done to optimize outcomes in Medicare negotiations? Contact us to learn more about our IRA support capabilities, and be sure to tune in to our webinar with Dr. Mark McClellan on September 12th: https://lnkd.in/gZ98SqJS #IRA #MedicareNegotiations #DrugPricing #CMS #LifeSciencesConsulting #IPAY2026

NEW Medicare negotiated prices reveal that some short- and long-term monopoly drugs received similar cuts from list price despite having vastly different statutory discounts. This surprising range of deviation raises questions about what matters most to CMS. Wondering what this means for subsequent rounds of negotiation? Tune in to our webinar on September 12th featuring former CMS commissioner Dr. Mark McClellan to learn more: https://lnkd.in/gZ98SqJS #IRA #MedicareNegotiations #DrugPricing #CMS #LifeSciencesConsulting #IPAY2026

Missed It? The recording of our recent webinar, “From Policy to Practice: How Prescription Drug Affordability Boards May Impact Patients” is now available! Watch the recording here: https://lnkd.in/gpU_EvVq #WebinarRecording #PDAB #DrugPricing #PatientAdvocacy #HealthPolicy 

Last chance! Register now for today's webinar, “From Policy to Practice: How Prescription Drug Affordability Boards May Impact Patients”: https://lnkd.in/gMusggXb Don’t miss out on expert insights on the implications Prescription Drug Affordability Boards may have for patients and opportunities for engagement. #Webinar #PDAB #DrugPricing #PatientAdvocacy #HealthPolicy 

On August 15, 2024, CMS released the final prices for the 10 drugs selected for Medicare negotiations for initial price applicability year 2026. Discounts above the statutory requirement illustrate the importance of contextual factors in CMS' decision-making and trends between products could shed light on the relative weighting of these. Innopiphany is a market leader in navigating the complexities of the IRA. We have first-hand experience helping manufacturers prepare, strategize, and engage with CMS. It's never too early to begin IRA Readiness, so contact our team today to find out more. #IRA #MedicareNegotiations #DrugPricing #CMS #LifeSciences #Consulting